The roles of glycated albumin as intermediate glycation index and pathogenic protein

Kwang Joon Kim, byungwan lee

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

The conventional glycemic indices used in management of diabetic patients includes A1c, fructosamine, 1,5-anhydroglucitol, and glycated albumin (GA). Among these indices, A1c is currently used as the gold standard. However, A1c cannot reflect the glycemic change over a relatively short period of time, and its accuracy is known to decrease when abnormalities in hemoglobin metabolism, such as anemia, coexist. When considering these weaknesses, there have been needs for finding a novel glycemic index for diagnosing and managing diabetes, as well as for predicting diabetic complications properly. Recently, several studies have suggested the potential of GA as an intermediate-term glycation index in covering the short-term effect of treatment. Furthermore, its role as a pathogenic protein affecting the worsening of diabetes and occurrence of diabetic complications is receiving attention as well. Therefore, in this article, we wanted to review the recent status of GA as a glycemic index and as a pathogenic protein.

Original languageEnglish
Pages (from-to)98-107
Number of pages10
JournalDiabetes and Metabolism Journal
Volume36
Issue number2
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Glycemic Index
Diabetes Complications
Fructosamine
Proteins
Anemia
Hemoglobins
glycosylated serum albumin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{028c42be14364d9b97b4a4fa148a559f,
title = "The roles of glycated albumin as intermediate glycation index and pathogenic protein",
abstract = "The conventional glycemic indices used in management of diabetic patients includes A1c, fructosamine, 1,5-anhydroglucitol, and glycated albumin (GA). Among these indices, A1c is currently used as the gold standard. However, A1c cannot reflect the glycemic change over a relatively short period of time, and its accuracy is known to decrease when abnormalities in hemoglobin metabolism, such as anemia, coexist. When considering these weaknesses, there have been needs for finding a novel glycemic index for diagnosing and managing diabetes, as well as for predicting diabetic complications properly. Recently, several studies have suggested the potential of GA as an intermediate-term glycation index in covering the short-term effect of treatment. Furthermore, its role as a pathogenic protein affecting the worsening of diabetes and occurrence of diabetic complications is receiving attention as well. Therefore, in this article, we wanted to review the recent status of GA as a glycemic index and as a pathogenic protein.",
author = "Kim, {Kwang Joon} and byungwan lee",
year = "2012",
month = "4",
day = "1",
doi = "10.4093/dmj.2012.36.2.98",
language = "English",
volume = "36",
pages = "98--107",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "2",

}

The roles of glycated albumin as intermediate glycation index and pathogenic protein. / Kim, Kwang Joon; lee, byungwan.

In: Diabetes and Metabolism Journal, Vol. 36, No. 2, 01.04.2012, p. 98-107.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The roles of glycated albumin as intermediate glycation index and pathogenic protein

AU - Kim, Kwang Joon

AU - lee, byungwan

PY - 2012/4/1

Y1 - 2012/4/1

N2 - The conventional glycemic indices used in management of diabetic patients includes A1c, fructosamine, 1,5-anhydroglucitol, and glycated albumin (GA). Among these indices, A1c is currently used as the gold standard. However, A1c cannot reflect the glycemic change over a relatively short period of time, and its accuracy is known to decrease when abnormalities in hemoglobin metabolism, such as anemia, coexist. When considering these weaknesses, there have been needs for finding a novel glycemic index for diagnosing and managing diabetes, as well as for predicting diabetic complications properly. Recently, several studies have suggested the potential of GA as an intermediate-term glycation index in covering the short-term effect of treatment. Furthermore, its role as a pathogenic protein affecting the worsening of diabetes and occurrence of diabetic complications is receiving attention as well. Therefore, in this article, we wanted to review the recent status of GA as a glycemic index and as a pathogenic protein.

AB - The conventional glycemic indices used in management of diabetic patients includes A1c, fructosamine, 1,5-anhydroglucitol, and glycated albumin (GA). Among these indices, A1c is currently used as the gold standard. However, A1c cannot reflect the glycemic change over a relatively short period of time, and its accuracy is known to decrease when abnormalities in hemoglobin metabolism, such as anemia, coexist. When considering these weaknesses, there have been needs for finding a novel glycemic index for diagnosing and managing diabetes, as well as for predicting diabetic complications properly. Recently, several studies have suggested the potential of GA as an intermediate-term glycation index in covering the short-term effect of treatment. Furthermore, its role as a pathogenic protein affecting the worsening of diabetes and occurrence of diabetic complications is receiving attention as well. Therefore, in this article, we wanted to review the recent status of GA as a glycemic index and as a pathogenic protein.

UR - http://www.scopus.com/inward/record.url?scp=84864619348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864619348&partnerID=8YFLogxK

U2 - 10.4093/dmj.2012.36.2.98

DO - 10.4093/dmj.2012.36.2.98

M3 - Review article

VL - 36

SP - 98

EP - 107

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 2

ER -